Free public records show Shanghai Golden Leaf MedTec Co. Ltd in 3 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Shanghai Golden Leaf MedTec Co. Ltd or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
4 active studies led by Shanghai Golden Leaf MedTec Co. Ltd, of 9 in all
Source: ClinicalTrials.gov, Studies with Shanghai Golden Leaf MedTec Co. Ltd (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Shanghai Golden Leaf MedTec Co. Ltd leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Shanghai Golden Leaf MedTec Co. Ltd or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Shanghai Golden Leaf MedTec Co. Ltd: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Shanghai Golden Leaf MedTec Co. Ltd is in.
Stories on the topics Shanghai Golden Leaf MedTec Co. Ltd works in.
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Breast cancer is the most common cancer in women worldwide. Finding it early saves lives, but access to…
ReadSearch all reports for Shanghai Golden Leaf MedTec Co. Ltd All companies